**Contents**



#### **Changyoon Ha, Heejin Kim, Rari Cha, Jaemin Lee, Sangsoo Lee, Jung-Hwa Ryu, Hyunjin Kim and Ok-Jae Lee**

Effect of DA-9701 on the Gastrointestinal Motility in the Streptozotocin-Induced Diabetic Mice Reprinted from: *J. Clin. Med.* **2021**, *10*, 5282, doi:10.3390/jcm10225282 ................ **213**

## **About the Editor**

**Marilena Durazzo** is presently the Head of Internal Medicine 3 Unit, Molinette Hospital of Turin, and a confirmed Associate Professor of Internal Medicine, University of Turin. She is also the Vice-Director of the General Hospital Department. She graduated in medicine in 1978, after which she then specialized in gastroenterology (1982). During 90s she was a visiting scientist in Internal Medicine, University of Hannover, Germany. Prof. Durazzo is the author of more than 140 publications in scientific international journals with impact factors, about 20 book chapters and a monograph. Nowadays, her main fields of scientific and research interest include chronic viral hepatitis, nonalcoholic steatohepatitis, metabolic syndrome and gastroenterological problems in the elderly.

## *Editorial* **Trends in the Comprehension and Management of Gastrointestinal Tract Disorders**

**Marilena Durazzo 1,\*, Arianna Ferro 1, Sharmila Fagoonee 2 and Rinaldo Pellicano 3**


During the last decade, relevant advances have been made in the knowledge of the pathogenetic mechanisms of gastrointestinal (GI) tract disorders. This has led to a better managemen<sup>t</sup> of these morbidities that, regarding the healthcare required for a longer lifespan, represent a significant burden for all national health systems around the world [1]. In fact, aging increases the risk for chronic and neoplastic diseases as well as the worsening of already existent disturbances [2].

The epidemiological changes that have occurred lately have been influenced by the improved managemen<sup>t</sup> of some health conditions, as well as exogenous factors. For instance, after the introduction of new drugs and new strategies for the cure of *Helicobacter pylori* infection—particularly, the single-capsule bismuth quadruple therapy [3] and the use of tailored approaches [4]—a drastic reduction in terms of the incidence and prevalence of this infection as well as other related morbidities (peptic ulcer disease) is expected [5]. On the other hand, the increasing prevalence of a more "Westernized" lifestyle (including dietary changes and a decrease in physical activity) has been associated with a diet rich in fat and protein, and a rise in the incidence of gastroesophageal reflux disease (GERD), which affects esophageal and extra-esophageal systems [6]. In parallel, this change in lifestyle has been associated with an increased incidence of metabolic-associated fatty liver disease (MAFLD) [7], which in the clinical setting, reflects in a shift from a higher prevalence of viral liver diseases to a higher prevalence of dysmetabolic liver diseases [8], as well as a significant increase in the incidence of malignancies as colorectal cancer (CRC). Within this negative context, the increased incidence of disorders caused by inappropriate alcohol consumption [9], associated with both hepatic and extra-hepatic alcohol-related disorders play a major role [10]. Since modifiable factors can be corrected after the appropriate education and psychological support, carrying out this task has become a priority.

Inflammatory bowel diseases (IBD) represent another prime example that highlights therapeutic improvements of GI tract disorders. The introduction, in the clinical setting, of biologic drugs has allowed the managemen<sup>t</sup> of IBD patients to become optimized for steroid-refractory or steroid-resistant diseases [11], improving not only the mucosal state (with a mucosal remission) but also the clinical consequences of this inflammation [12]. These advances have allow us to focus on the endpoint beyond the clinical and endoscopic parameters, including the patient's quality of life [13].

Increasingly often, the interdisciplinary aspect of GI pathologies is the object of studies that aim to optimize the managemen<sup>t</sup> of patients with complex diseases, a prime example being the managemen<sup>t</sup> of GI conditions in diabetic patients. Nevertheless, despite the intense efforts made from basic research [14] to the clinical setting [15], diabetic gastroparesis remains a challenge for clinicians. The involvement of the hepato-pancreato-biliary tract in the context of autoimmune manifestations is another key example of this [16]. While some

**Citation:** Durazzo, M.; Ferro, A.; Fagoonee, S.; Pellicano, R. Trends in the Comprehension and Management of Gastrointestinal Tract Disorders. *J. Clin. Med.* **2022**, *11*, 1730. https://doi.org/10.3390/jcm11061730

Received: 18 March 2022 Accepted: 18 March 2022 Published: 21 March 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

diseases, such as autoimmune hepatitis and primary biliary cholangitis, are well-known, others, such as autoimmune pancreatitis, represent a challenge for clinicians in several fields (gastroenterologists, experts in endoscopic or radiologic imaging, and immunologists). In the presence of these conditions, a multidisciplinary approach is essential to determine both the appropriate diagnosis and optimal treatment for managing patients, whilst avoiding undervaluation, overmedicalization and unnecessary costs.

The emergence of microbiota–microbiome investigations into the spotlight has opened a door to several research possibilities and could, in theory, help to offer therapeutic interventions for a broad series of GI diseases. These interventions could range from benign, non-inflammatory [17] or inflammatory types [18] to malignant diseases [19].

Finally, the current pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has drastically impacted human society, causing not only diseases of the respiratory tract [20] but also of the digestive tract [21]. Furthermore, some GI conditions, such as bleeding and the increased the risk of death among patients with coronavirus disease-19 (COVID-19), were discovered [22]. Patients affected by COVID-19 also experienced an increase in GI symptoms, but this was not associated with hospitalization or mortality rates [23]. This could be due to the fact that a relevant part of these manifestations were likely to have had an anxiety-induced functional basis. This has also been associated with GI disturbances reported by medical students during the COVID-19 lockdown periods [24].

**Author Contributions:** Conceptualization, M.D. and R.P.; writing—original draft preparation, A.F. and R.P.; writing—review and editing, S.F.; supervision, M.D. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We apologize to all the investigators whose important works have not been cited due to space restrictions.

**Conflicts of Interest:** The authors declare no conflict of interest.
